Bal Pharma (NSE:BALPHARMA) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BALPHARMA Bal Pharma Ltd NSE:BALPHARMA
68 GF Score
Price ₹95.38
GF Value ₹103.43
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bal Pharma Marketable Securities?

Bal Pharma NSE:BALPHARMA +2.90% 68 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:BALPHARMA with a GF Score™ of 68/100 and a GF Value™ of ₹103.43 (Fairly Valued). The stock has 8 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Bal Pharma's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Bal Pharma's annual Marketable Securities declined from Mar. 2024 (₹157 Mil) to Mar. 2025 (₹87 Mil) and declined from Mar. 2025 (₹87 Mil) to Mar. 2026 (₹69 Mil).

Bal Pharma  (NSE:BALPHARMA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Bal Pharma Marketable Securities Related Terms

Bal Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Bal Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bal Pharma Marketable Securities Chart

Bal Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.72 59.76 157.33 86.59 69.07

Bal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 90.75 0.00 69.07 0.00
NSE:BALPHARMA
68GF Score
Bal Pharma Ltd NSE:BALPHARMA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bal Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Bal Pharma (NSE:BALPHARMA) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bal Pharma and its competitors.
Is Bal Pharma's Marketable Securities too high?
Bal Pharma's current Marketable Securities is ₹0 Mil. Overall, Bal Pharma has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bal Pharma's Marketable Securities compare to ZTS?
Bal Pharma's Marketable Securities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bal Pharma and its competitors. Bal Pharma's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bal Pharma (NSE:BALPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹103.43, compared to a current price of ₹95.38 — trading 7.8% below its estimated fair value. The current Marketable Securities is ₹0 Mil. Bal Pharma's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Bal Pharma (NSE:BALPHARMA), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bal Pharma (NSE:BALPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Bal Pharma stock appears to be undervalued. The current stock price of ₹95.38 is trading 7.8% below its estimated GF Value™ of ₹103.43. GuruFocus considers Bal Pharma to be Fairly Valued.

Key valuation signals for NSE:BALPHARMA:

  • Marketable Securities: ₹0 Mil
  • GF Value™: ₹103.43 vs. price of ₹95.38 (7.8% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the NSE:BALPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bal Pharma Business Description

Other Exchanges 524824:India
Address 10/1, Palace Road, 5th Floor, Lakshmi Narayan Complex, Bengaluru, KA, IND, 560052
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives.
68GF Score

Get the complete analysis for NSE:BALPHARMA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹95.38
Price
₹103.43
GF Value